January 2023

BALTIMORE, January 26, 2023 – Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies using its controllable self-replicating RNA (c-srRNA) platform, today announced that it has entered a memorandum of understanding with Hitachi Global Life Solutions, Inc. (Hitachi GLS) for the development of Micro GMP suites to facilitate

BALTIMORE, Jan. 04, 2023 — Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies using its controllable self-replicating RNA (c-srRNA) platform, today announced that members of the management team will be attending the Biotech Showcase Conference taking place January 9-11, 2023 in San Francisco, California. Akihiro Ko, chief